Biological Response Determinants in HSV-tk + Ganciclovir Gene Therapy for Prostate Cancer
Open Access
- 1 April 2006
- journal article
- Published by Elsevier BV in Molecular Therapy
- Vol. 13 (4), 716-728
- https://doi.org/10.1016/j.ymthe.2005.11.022
Abstract
No abstract availableKeywords
This publication has 26 references indexed in Scilit:
- Prostate-Specific Antigen Response and Systemic T Cell Activation After In Situ Gene Therapy in Prostate Cancer Patients Failing RadiotherapyHuman Gene Therapy, 2001
- In situ gene therapy for prostate cancer: immunomodulatory approachesExpert Opinion on Biological Therapy, 2001
- Human prostate carcinoma cells as targets for herpes simplex virus thymidine kinase–mediated suicide gene therapyCancer Gene Therapy, 2001
- Gene therapy for prostate cancerUrology, 2001
- Prostate-specific suicide gene therapy using the prostate-specific membrane antigen promoter and enhancerThe Prostate, 2000
- Cytopathic effect of in situ gene therapy in prostate cancerHuman Pathology, 2000
- Adenovirus‐mediated suicide‐gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: changes in tumour cell proliferative activityBJU International, 2000
- DEVELOPMENT OF PROSTATE-SPECIFIC ANTIGEN PROMOTER-BASED GENE THERAPY FOR ANDROGEN-INDEPENDENT HUMAN PROSTATE CANCERJournal of Urology, 1998
- A Preoperative Nomogram for Disease Recurrence Following Radical Prostatectomy for Prostate CancerJNCI Journal of the National Cancer Institute, 1998
- National Patterns of Prostate Cancer Treatment by Radical Prostatectomy: Results of a Survey by the American College of Surgeons Commission on CancerJournal of Urology, 1994